Amneal Pharmaceuticals (AMRX) Debt/Equity Ratio: History & Chart

Amneal Pharmaceuticals, Inc.(AMRX)

Drug Manufacturers - Specialty & Generic · Bridgewater, NJ

$20.09-0.26 (-1.26%)

Delayed quote: Oct 6, 2026, 10:20 AM EDT

About Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.

Bridgewater, NJ

8,700 employees

www.amneal.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Chirag K. Patel

View full financials

AMRX Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

84.54

DEBT TO EQUITY RATIO AVG TTM

-12.20

DEBT TO EQUITY RATIO AVG 3Y

-26.38

DEBT TO EQUITY RATIO AVG 5Y

-11.52

DEBT TO EQUITY RATIO AVG 10Y

2.45

DEBT TO EQUITY RATIO AVG 15Y

N/A

DEBT TO EQUITY RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

+793.20%

CURRENT VS 3Y AVG

+420.45%

CURRENT VS 5Y AVG

+833.95%

CURRENT VS 10Y AVG

+3350.40%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.14

median of 516 covered companies

CURRENT VS SECTOR MEDIAN

+62520.25%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Amneal Pharmaceuticals, Inc. (AMRX)	$6.40B	84.54	-12.20	-26.38	-11.52
GRAIL Inc. (GRAL)vs ›	$6.30B	0.04	0.04	0.03	0.04
Hims & Hers Health, Inc. (HIMS)vs ›	$6.50B	4.77	1.04	0.53	0.36
Lantheus Holdings, Inc. (LNTH)vs ›	$6.53B	0.48	0.57	0.80	0.68
Chemed Corporation (CHE)vs ›	$6.66B	0.40	0.15	0.19	0.23
Immunovant, Inc. (IMVT)vs ›	$6.62B	0.00	0.00	0.00	0.00
Ligand Pharmaceuticals Incorporated (LGND)vs ›	$5.97B	1.17	0.23	0.15	0.27
Iovance Biotherapeutics, Inc. (IOVA)vs ›	$5.85B	0.06	0.08	0.11	0.11
Alkermes plc (ALKS)vs ›	$6.96B	0.87	0.04	0.19	0.25
CG Oncology Inc. (CGON)vs ›	$5.76B	0.01	0.01	0.04	0.11

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Amneal Pharmaceuticals, Inc. (AMRX)

$6.40B

84.54

-12.20

-26.38

-11.52

GRAIL Inc. (GRAL)vs ›

$6.30B

0.04

0.03

0.04

Hims & Hers Health, Inc. (HIMS)vs ›

$6.50B

4.77

1.04

0.53

0.36

Lantheus Holdings, Inc. (LNTH)vs ›

$6.53B

0.48

0.57

0.80

0.68

Chemed Corporation (CHE)vs ›

$6.66B

0.40

0.15

0.19

0.23

Immunovant, Inc. (IMVT)vs ›

$6.62B

0.00

Ligand Pharmaceuticals Incorporated (LGND)vs ›

$5.97B

1.17

0.23

0.15

0.27

Iovance Biotherapeutics, Inc. (IOVA)vs ›

$5.85B

0.06

0.08

0.11

Alkermes plc (ALKS)vs ›

$6.96B

0.87

0.04

0.19

0.25

CG Oncology Inc. (CGON)vs ›

$5.76B

0.01

0.04

0.11

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Amneal Pharmaceuticals, Inc. (AMRX)?

The debt to equity ratio for AMRX stock is 84.54.

Is Amneal Pharmaceuticals, Inc.'s debt to equity ratio high or low?

The debt to equity ratio of 84.54 is 834% above its 5-year average of -11.52, near the high end of its 5-year range (-59.38–139.05).

What is the TTM average debt to equity ratio for Amneal Pharmaceuticals, Inc. (AMRX)?

The TTM average debt to equity ratio for AMRX stock is -12.20.

What is the 3Y average debt to equity ratio for Amneal Pharmaceuticals, Inc. (AMRX)?

The 3Y average debt to equity ratio for AMRX stock is -26.38.

What is the 5Y average debt to equity ratio for Amneal Pharmaceuticals, Inc. (AMRX)?

The 5Y average debt to equity ratio for AMRX stock is -11.52.

What is the 10Y average debt to equity ratio for Amneal Pharmaceuticals, Inc. (AMRX)?

The 10Y average debt to equity ratio for AMRX stock is 2.45.

DATE	DEBT TO EQUITY RATIO
2026-06-30	84.54
2026-03-31	-59.38
2025-12-31	-38.65
2025-09-30	-24.54
2025-06-30	-22.94
2025-03-31	-19.59
2024-12-31	-23.73
2024-09-30	-28.31
2024-06-30	-47.42
2024-03-31	-43.09
2023-12-31	139.05
2023-09-30	8.48
2023-06-30	8.98
2023-03-31	9.69
2022-12-31	9.53
2022-09-30	9.61
2022-06-30	10.34
2022-03-31	7.33
2021-12-31	8.01
2021-09-30	8.31
2021-06-30	8.52
2021-03-31	9.04
2020-12-31	9.89
2020-09-30	9.84
2020-06-30	9.72
2020-03-31	10.30
2019-12-31	11.94
2019-09-30	7.01
2019-06-30	6.05
2019-03-31	5.91
2018-12-31	3.00
2018-09-30	5.74
2018-06-30	5.62
2018-03-31	0.00
2017-12-31	-3.85
2017-09-30	-3.35
2017-06-30	0.00
2017-03-31	0.00
2016-12-31	-6.46

DATE

DEBT TO EQUITY RATIO

2026-06-30

84.54

2026-03-31

-59.38

2025-12-31

-38.65

2025-09-30

-24.54

2025-06-30

-22.94

2025-03-31

-19.59

2024-12-31

-23.73

2024-09-30

-28.31

2024-06-30

-47.42

2024-03-31

-43.09

2023-12-31

139.05

2023-09-30

8.48

2023-06-30

8.98

2023-03-31

9.69

2022-12-31

9.53

2022-09-30

9.61

2022-06-30

10.34

2022-03-31

7.33

2021-12-31

8.01

2021-09-30

8.31

2021-06-30

8.52

2021-03-31

9.04

2020-12-31

9.89

2020-09-30

9.84

2020-06-30

9.72

2020-03-31

10.30

2019-12-31

11.94

2019-09-30

7.01

2019-06-30

6.05

2019-03-31

5.91

2018-12-31

3.00

2018-09-30

5.74

2018-06-30

5.62

2018-03-31

0.00

2017-12-31

-3.85

2017-09-30

-3.35

2017-06-30

0.00

2017-03-31

0.00

2016-12-31

-6.46

Debt to Equity Ratio: 84.54

AMRX Debt to Equity Ratio

AMRX Average Debt to Equity Ratio Chart

AMRX Current vs Average Debt to Equity Ratio Chart

AMRX Debt to Equity Ratio Metrics

AMRX Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

AMRX Debt to Equity Ratio History

Related Metrics